Découvrez nos professeurs et professeures!

Yves Fradet

Médecin clinicien enseignant titulaire

Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :
Ce profil n’a pas encore été complété.

Contribution à la recherche

Projets de recherche

  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2021-10-01 au 2026-09-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma - Société de recherche sur le cancer - UpCycle 2.1, chercheur principal - 2022-08-01 au 2026-07-31
  • Testing of Biological Activity of DPX-Survivac in vivo in HLA-A1 and HLA-B7 mice - ImmunoVaccine Technologies Inc., chercheur principal - 2020-11-20 au 2025-12-25
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2023-02-22 au 2024-06-01
  • Developement of a prostate cancer vaccine - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2022-07-20 au 2023-07-19
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers - The W. Garfield Weston Foundation - Transformational Research, co-chercheur - 2020-06-01 au 2023-05-31
  • Biobanque en urologie - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-03-03 au 2023-05-01
  • Biobanque en urologie - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2022-05-01 au 2023-04-30
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines - Fondation du CHU de Québec, chercheur principal - 2022-03-22 au 2023-03-21
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer - Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Société canadienne du cancer - Initiative SCC/IC-IRSC en prévention primaire du cancer, co-chercheur - 2022-01-15 au 2023-01-14
  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate - Merck Canada Inc., Consortium québécois sur la découverte du médicament, Fondation du CHU de Québec - Quantum Leap, chercheur principal - 2019-12-01 au 2022-11-30
  • Intégration de l'imagerie par résonance magnétique multiparamétrique dans la trajectoire diagnostique des patients avec suspicion de cancer de la prostate au CHU de Québec - Université Laval - Ministère de l'Économie et de l'Innovation - Programme de soutien aux organismes de recherche et d’innovation (PSO) - Volet 2 : Soutien aux projets, co-chercheur - 2020-06-15 au 2022-09-30
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer - The W. Garfield Weston Foundation, co-chercheur - 2020-09-01 au 2022-08-31
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer - Instituts de recherche en santé du Canada - Subvention Projet, University of British Columbia, co-chercheur - 2017-04-01 au 2022-03-31
  • Développement d'une nouvelle thérapie d'activation de cellules T combinant des peptides MAGE-A9 et survivine utilisant la plateforme DPX d'IMV pour évaluer son activité préclinique et clinique dans le cancer de la vessie - Consortium québécois sur la découverte du médicament, ImmunoVaccine Technologies Inc., Fondation du CHU de Québec - Programme conjoint CQDM/Alsace BioValley, chercheur principal - 2019-04-01 au 2022-03-31
  • Identification des anomalies génétiques du cancer de la prostate et de leur impact clinique - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-04-01 au 2022-03-31

Publications

  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Pouliot F, Lacombe L, Fradet Y, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc S, Blouin AC, Blais AS, Paquet S, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark., Lockhard C, Fradet Y, The Canadian journal of urology, 1997
  • Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials, Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Arjun V. Balar, Dean F. Bajorin, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt, 2023, 10.1158/1078-0432.22487295
  • Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2., Lacombe L, Fradet Y, Larue H, Latulippe E, Hovington H, Moore K, Lessard A, Aziz A, BJU international, 2010, 10.1111/j.1464-410x.2010.09909.x
  • P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers., Fradet Y, Têtu B, Meyer F, Moore L, Pfister C, Normand C, Simoneau M, Allard P, LaRue H, Carcinogenesis, 2000, 10.1093/carcin/21.1.101
  • Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery., Shariat SF, Sonpavde G, Fritsche HM, Müller SC, Montorsi F, Kassouf W, Izawa JI, Fradet Y, Skinner E, Karakiewicz PI, Svatek RS, Bastian PJ, Novara G, Nuhn P, Urologia internationalis, 2011, 10.1159/000325463
  • Abstraits AUQ 2013, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013
  • Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies., Tilups A, Bootsma G, McGroarty R, Choi BC, Wang Y, He S, Hanna W, Connolly JG, Fradet Y, de Harven E, Cancer research, 1992
  • Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer., Bernard P, Roberge N, Fradet Y, Allard P, Têtu B, Human pathology, 1996, 10.1016/s0046-8177(96)90219-1
  • Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes., Shariat SF, Stenzl A, Sievert KD, Pycha A, Lerner SP, Lee CT, Hautmann RE, Fradet Y, Daneshmand S, Dalbagni G, Bochner B, Artibani W, Abol-Enein H, Lee RK, BJU international, 2014, 10.1111/bju.12121
  • Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study., Fradet Y, Farooq U, Validire P, Huntsman D, Wu TT, Meyers MO, Resnick MB, Pipas JM, Clancy TE, Kellner U, Everson RB, Louvet C, Gill S, Shi Q, Sargent DJ, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2659
  • 2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • The management of high-risk prostate cancer in 2008., Fradet Y, World journal of urology, 2008, 10.1007/s00345-008-0261-4
  • p53 immunohistochemistry in bladder cancer--a new approach to an old question., International Study-Initiative on Bladder Cancer (ISBC), Schmitz-Dräger BJ, Groshen SG, Goebell PJ, Urologic oncology, 2010, 10.1016/j.urolonc.2010.03.021
  • [Modulation of lymphocyte proliferation by serum factors and lipopolysaccharide], Daguillard F, Boncy J, Fradet Y, Annales d'immunologie, 1977
  • Critical appraisal of tumor markers in bladder cancer., Fradet Y, Cordon-Cardo C, Seminars in urology, 1993
  • Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors., Boutros PC, Lacombe L, Berlin A, Murgic J, Hovington H, Orain M, Picard V, Yao CQ, Zheng J, Meng A, Haider S, Fraser M, Chua MLK, Alkallas R, Lalonde E, European urology, 2016, 10.1016/j.eururo.2016.10.013
  • Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis., Jewett MA, Fradet Y, Sampson HA, Spiess PE, Redelmeier DA, Nam RK, The Journal of urology, 2000, 10.1016/s0022-5347(05)67797-x
  • Toll-like receptors in urothelial cells--targets for cancer immunotherapy., Bergeron A, Fradet Y, Ayari C, LaRue H, Nature reviews. Urology, 2013, 10.1038/nrurol.2013.153
  • p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?, Fradet Y, Ebert T, Goebell PJ, Schmitz-Dräger BJ, European urology, 2000, 10.1159/000020364
  • Use of markers in defining urothelial premalignant and malignant conditions., Tribukait B, Fradet Y, Schmitz-Dräger B, Grossman HB, Scandinavian journal of urology and nephrology. Supplementum, 2000, 10.1080/003655900750169347
  • IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness., Fradet V, Fradet Y, Ayari C, LaRue H, Bergeron A, Deschênes-Rompré MP, Moreel X, Neveu B, Research and reports in urology, 2014, 10.2147/rru.s58643
  • Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada., Black P, Jacobson NE, Fairey A, Fradet Y, Lacombe L, Saad F, Lattouf JB, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Kassouf W, Metcalfe M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12146
  • Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery., Upper Tract Urothelial Carcinoma Collaboration (UTUCC), Daneshmand S, Hansen J, Novara G, Lee RK, Fajkovic H, Svatek RS, Raman JD, Margulis V, Babjuk M, Karakiewicz PI, Green DA, Cha EK, Ehdaie B, Rink M, European urology, 2012, 10.1016/j.eururo.2012.02.018
  • Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer., Shariat SF, Netto G, Heukamp LC, Rigaud J, Müller SC, Nielsen ME, Bastian PJ, Montorsi F, Capitanio U, Ashfaq R, Fradet Y, Karakiewicz PI, Lotan Y, Margulis V, Journal of the National Cancer Institute, 2009, 10.1093/jnci/djn451
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Identification of two genes differentially expressed upon different spatial configuration of the MGH-U3 human bladder cancer cells., Bachvarov D, Fradet Y, Champetier S, Urologic oncology, 2002, 10.1016/s1078-1439(01)00130-2
  • Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference., Tribukait B, Fradet Y, de Vere White RW, Badalament RA, Wheeless LL, Cytometry, 1993, 10.1002/cyto.990140504
  • Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells., Hurst RE, Min KW, Rao JY, Fradet Y, Hemstreet GP, Bonner RB, Cancer, 1993, 10.1002/1097-0142(19931015)72:8<2461::aid-cncr2820720826>3.0.co;2-c
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial., Klotz L, Guillemette C, Lévesque É, Fradet Y, Pouliot F, Caron P, Turcotte V, Joncas FH, Ding K, Hoffman A, Toren P, Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 10.1158/1078-0432.ccr-18-1187
  • Genetic and molecular markers in the prognosis of bladder cancer., Yoshida O, Uchida T, Schalken JA, Kubota Y, Fradet Y, Urologic oncology, 1998, 10.1016/s1078-1439(99)00021-6
  • Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics., Old LJ, Melamed MR, Whitmore WF, Cordon-Cardo C, Fradet Y, Cancer research, 1986
  • ABSTRAITS AUQ 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4968
  • Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis., Svatek RS, Ficarra V, Tilki D, Lotan Y, Skinner EC, Izawa JI, Fritsche HM, Karakiewicz PI, Kassouf W, Fradet Y, Novara G, Dinney CP, Shariat SF, Messer JC, Urology, 2014, 10.1016/j.urology.2013.10.060
  • Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram., Haese A, Fradet Y, Schalken JA, van Gils MP, Stillebroer AB, Abbou CC, Huland H, Mulders PF, Stenzl A, Marberger M, van Poppel H, de la Taille A, Chun FK, European urology, 2009, 10.1016/j.eururo.2009.03.029
  • Recent advances in the management of superficial bladder tumors., Fradet Y, The Canadian journal of urology, 2002
  • Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study., Labrie F, Candas B, Diamond P, Suburu ER, Cusan L, Gomez J, Dupont A, Fradet Y, Ttu B, Vailancourt L, The American journal of surgical pathology, 1996, 10.1097/00000478-199601000-00010
  • Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data., Droit A, Fradet Y, Bergeron A, Perin O, Scott Boyer MP, Martin-Magniette ML, Vittrant B, Leclercq M, Frontiers in genetics, 2019, 10.3389/fgene.2019.00452
  • Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group., Laplante S, Bullock MJ, Paquin JM, Chin J, Barkin J, Fradet Y, Mador D, Jewett MA, Srigley J, Klotz LH, Goldenberg SL, The Journal of urology, 1996, 10.1016/s0022-5347(01)65645-3
  • An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study., Chin J, Zarenda M, Kebabdjian M, Fradet Y, Aprikian A, Singal R, Drachenberg D, Klotz L, Prostate cancer and prostatic diseases, 2014, 10.1038/pcan.2014.24
  • Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer., TITAN Investigators, Ye D, Uemura H, Özgüroğlu M, Merseburger AS, Juárez Soto Á, Given R, Pereira de Santana Gomes AJ, Chung BH, Bjartell A, Agarwal N, Chi KN, The New England journal of medicine, 2019, 10.1056/nejmoa1903307
  • Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis., Têtu B, Meyer F, Fradet Y, Trudel D, Human pathology, 2010, 10.1016/j.humpath.2010.05.001
  • Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data., Jocham D, Jichlinski P, Stenzl A, Witjes JA, Burgués JP, Karl A, Fradet Y, Ray E, Drăgoescu O, Hermann G, Schmidbauer J, Droller M, Grossman HB, Burger M, European urology, 2013, 10.1016/j.eururo.2013.03.059
  • Insomnia in men treated with radical prostatectomy for prostate cancer., Fradet Y, Lacombe L, Ivers H, Hervouet S, Simard S, Savard J, Psycho-oncology, 2005, 10.1002/pon.830
  • Gleason grading controversies: what the chemoprevention trials have taught us., Zlotta A, Trachtenberg J, Saad F, Fradet Y, Drachenberg D, Klotz L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1115
  • Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization., Fradet Y, LaRue H, Bergeron A, The Biochemical journal, 1997, 10.1042/bj3210889
  • [The PATCHED/Sonic Hedgehog signalling pathway in superficial bladder cancer]., Fradet Y, Jeannotte L, Hovington H, Hamed S, Girard J, Lemieux P, Aboulkassim TO, Simoneau M, LaRue H, Medecine sciences : M/S, 2003, 10.1051/medsci/20031910920
  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy., Fradet V, Robitaille K, Fradet Y, Tiguert R, Dujardin T, Lodde M, Toren P, Lacombe L, Singbo N, Pelletier JF, Fradet S, Clinical nutrition ESPEN, 2021, 10.1016/j.clnesp.2021.12.011
  • Substratification of high-risk localised prostate cancer treated by radical prostatectomy., Fradet Y, Lacombe L, Harel F, Lodde M, World journal of urology, 2008, 10.1007/s00345-008-0252-5
  • [The treatment of localized cancer of the prostate using radioactive iodine implants]., Beaudoin L, Laverdière J, Fradet Y, L'union medicale du Canada, 1985
  • Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1181
  • Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies., Tardif M, Parent-Vaugeois C, Islam N, Boucher L, Fradet Y, Proceedings of the National Academy of Sciences of the United States of America, 1987, 10.1073/pnas.84.20.7227
  • Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7599
  • Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA., Chinnaiyan AM, Varambally R, Day JR, Penabella Y, Blase A, Meinke J, Hodge P, Williamsen S, Miick S, Sefton-Miller L, Lonigro RJ, Siddiqui J, Aubin SM, Tomlins SA, Science translational medicine, 2011, 10.1126/scitranslmed.3001970
  • Message from our President, Romao R, Filler G, Bjazevic J, Wang Z, Berto F, Gilling P, Kaplan S, Roehrborn R, Desai M, Paterson R, So A, Goldenberg S, Elterman D, Bhojani N, Zorn K, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Lymphadenectomy for bladder cancer at the time of radical cystectomy., Bochner BH, Shariat SF, Sagalowsky A, Lerner SP, Fritsche HM, Fradet Y, Evans CP, Colombo R, Brausi M, Tilki D, European urology, 2013, 10.1016/j.eururo.2013.04.036
  • Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience., Drachenberg D, Kassouf W, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin J, Aprikian A, Sandhu GS, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11276
  • 2011 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies., Bristow RG, Hoogland AM, Verhoef EI, van Leenders GJLH, Kweldam CF, Gopalan A, Mahamud O, Bhandari V, Lalonde E, Murgic J, Lo W, Pintilie M, Chua MLK, European urology, 2017, 10.1016/j.eururo.2017.04.034
  • Radioimmunodetection of human bladder tumor xenografts in nude mice with radiolabeled monoclonal antibodies., Caron C, Dufour C, Leclerc J, Guertin B, Friede J, Fradet Y, The Journal of urology, 1992, 10.1016/s0022-5347(17)36620-x
  • Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder., Bernard P, Têtu B, Fradet Y, Allard P, Clinical cancer research : an official journal of the American Association for Cancer Research, 1995
  • Total androgen ablation: Canadian experience., Tewari HD, Venner PM, Trachtenberg J, Ramsey EW, Laroche B, Fradet Y, Elhilali M, Béland G, The Urologic clinics of North America, 1991
  • Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors., Naud A, Charrois R, Bédard G, Bois R, Têtu B, Meyer F, Fradet Y, Grégoire M, The Journal of urology, 1997, 10.1016/s0022-5347(01)64827-4
  • Dietary fat and advanced prostate cancer., Moore L, Fradet Y, Meyer F, Bairati I, The Journal of urology, 1998, 10.1016/s0022-5347(01)63579-1
  • Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy., Fradet Y, Mian M, Puppo P, Naselli A, Lacombe L, Lodde M, World journal of urology, 2012, 10.1007/s00345-012-0827-z
  • Role of radical prostatectomy in high-risk prostate cancer., Fradet Y, The Canadian journal of urology, 2002
  • Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer., Fradet Y, Lacombe L, Bairati I, Têtu B, Meyer F, The Canadian journal of urology, 2006
  • Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder., Huland H, Huland E, Fradet Y, Schwaibold H, Lee E, The Journal of urology, 1997, 10.1016/s0022-5347(01)65143-7
  • The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence., Kassouf W, Bell D, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen NE, Rendon R, Lacombe L, Shayegan B, Allard CB, Dason S, Kapoor A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014, 10.5489/cuaj.1985
  • Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma., Fradet Y, Saourine A, Morin F, Friede J, Lacombe L, Lodde M, BJU international, 2010, 10.1111/j.1464-410x.2010.09212.x
  • The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder., Dinney CP, Izawa JI, Müller SC, Fritsche HM, Karakiewicz PI, Kassouf W, Bastian PJ, Fradet Y, Lerner SP, Novara G, Skinner EC, Lasky RE, Shariat SF, Svatek RS, Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, 10.1158/1078-0432.ccr-10-0457
  • Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network., Faraggi D, Wheeless LL, Chew K, Waldman FM, Hemstreet GP, Grossman HB, Fradet Y, Cordon-Cardo C, Charytonowicz E, Lianes P, Clinical cancer research : an official journal of the American Association for Cancer Research, 1998
  • Accelerated induction of bladder cancer in patched heterozygous mutant mice., Fradet Y, Latulippe E, Jeannotte L, Girard J, Hovington H, LaRue H, Hamed S, Cancer research, 2004, 10.1158/0008-5472.can-03-2031
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., Wu L, Lacombe L, Fradet Y, Bollag G, West BL, Xu J, Deng G, Sung JL, Magyar C, Pouliot F, Jiang Z, Moughon D, Priceman SJ, Liu C, Schokrpur S, Escamilla J, Cancer research, 2015, 10.1158/0008-5472.can-14-0992
  • Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome., Kassouf W, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Chin J, Lacombe L, Black P, Kapoor A, Izawa J, Fairey A, Jacobsen N, Rendon R, Tanguay S, Yafi FA, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.014
  • Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy., Labrie F, Diamond P, Cusan L, Gomez J, Dupont A, Fradet Y, Têtu B, Van der Kwast TH, The Prostate, 1996, 10.1002/(sici)1097-0045(199604)28:4<227::aid-pros3>3.0.co;2-a
  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group., Bajamonde A, Paton V, Moore MJ, Klotz LH, Saad F, Venner P, Davis I, Fradet Y, Elhilali M, Gleave ME, The New England journal of medicine, 1998, 10.1056/nejm199804303381804
  • PROGRAMME SCIENTIFIQUE : Vendredi, le 14 novembre 2008, Session scientifique V, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Réfutation: Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate? : OUI, Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Biological markers of prognosis in invasive bladder cancer., Fradet Y, Seminars in oncology, 1990
  • Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12272
  • Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Caron P, Bao BY, Douville P, Huang SP, Flageole C, Audet-Walsh É, Bellemare J, Nadeau G, The Journal of clinical endocrinology and metabolism, 2011, 10.1210/jc.2011-1049
  • Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., Guillemette C, Fradet Y, Harvey M, Nguile-Makao M, Caron A, Hovington H, Bergeron A, Larue H, Pouliot F, Lévesque É, Fradet V, Lacombe L, Cancer prevention research (Philadelphia, Pa.), 2015, 10.1158/1940-6207.capr-15-0069
  • Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression., Guillemette C, Droit A, Leclercq M, Villeneuve L, Caron P, Turcotte V, Brisson H, Rouleau M, Melo-Garcia L, Allain ÉP, Hovington H, Labriet A, Lévesque E, British journal of cancer, 2020, 10.1038/s41416-020-0749-2
  • Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth., Fradet V, Julien P, Fradet Y, Durand T, Bergeron A, Galano JM, Oger C, Roy J, Robitaille K, Larose J, Gevariya N, Bilodeau JF, Prostaglandins, leukotrienes, and essential fatty acids, 2020, 10.1016/j.plefa.2020.102215
  • 2015 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer., Droit A, Fradet Y, Bergeron A, Collins C, Martin-Magniette ML, Leclercq M, Vittrant B, Frontiers in genetics, 2020, 10.3389/fgene.2020.550894
  • Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes., Fradet Y, Sargent DJ, Têtu B, Grossman SR, Lyle S, Heald JI, Hafer LJ, Desaulniers M, Garon G, L'espérance S, Beaudry G, Houde M, Haince JF, Journal of clinical pathology, 2010, 10.1136/jcp.2009.072983
  • Canadian Consensus Conference: The FDA decision on the use of 5ARIs., Penson D, Parnes H, Klein E, Zlotta A, So A, Sugar L, Siemens R, Nickel JC, Goldenberg L, Fradet Y, Fleshner N, Finelli T, Chin J, Chetner M, Klotz L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12058
  • Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer., Fradet Y, Têtu B, Lacombe L, Bédard C, Bairati I, Meyer F, Urology, 2001, 10.1016/s0090-4295(01)01245-6
  • Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus., Shariat SF, Ogawa O, Malmstrom PU, Hemstreet GP, Fradet Y, Marberger MJ, van Rhijn BW, Hudson MA, Lotan Y, Lokeshwar VB, Droller M, Schmitz-Dräger BJ, Urologia internationalis, 2014, 10.1159/000369357
  • Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience., Kassouf W, Drachenberg D, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, BJU international, 2010, 10.1111/j.1464-410x.2010.09912.x
  • Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer., Shariat SF, Izawa JI, Fritsche HM, Dinney CP, Fradet Y, Kassouf W, Tilki D, Skinner E, Karakiewicz PI, Novara G, Svatek RS, Lerner SP, Khan MM, Sonpavde G, The Journal of urology, 2010, 10.1016/j.juro.2010.09.110
  • Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate., Trudel D, Saad F, Fradet Y, Bergeron A, Hovington H, Delvoye N, Kougioumoutzakis A, Diop MK, Albadine R, Cancers, 2021, 10.3390/cancers13246243
  • The role of neoadjuvant androgen deprivation prior to radical prostatectomy., Fradet Y, The Urologic clinics of North America, 1996, 10.1016/s0094-0143(05)70337-2
  • Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer., Chopin DK, Fradet Y, Abbou CC, Bellot J, Patard JJ, Bastuji S, Popov Z, Colombel M, Ravery V, British journal of cancer, 1995, 10.1038/bjc.1995.40
  • Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials, Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Arjun V. Balar, Dean F. Bajorin, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt, 2023, 10.1158/1078-0432.c.6532491
  • The assessment of disease aggressivity in stage D2 prostate cancer patients (review)., Fradet Y, Thabet M, Laroche B, Koutsilieris M, Anticancer research, 1990
  • Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling., Shariat SF, Scherr DS, Kassouf W, Fritsche HM, Svatek RS, Daneshmand S, Fradet Y, Pycha A, Green DA, Novara G, Trinh QD, Rink M, Sun M, Cha EK, Xylinas E, British journal of cancer, 2012, 10.1038/bjc.2012.464
  • Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort., Dinney CP, Ficarra V, Tilki D, Izawa JI, Fritsche HM, Karakiewicz PI, Kassouf W, Kamat AM, Bastian PJ, Fradet Y, Skinner EC, Novara G, Shariat SF, Svatek RS, BJU international, 2011, 10.1111/j.1464-410x.2010.09628.x
  • The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression., Lévesque E, Guillemette C, Lacombe L, Fradet Y, Têtu B, Simonyan D, Villeneuve L, Brisson H, Caron P, Garcia L, Hovington H, Belledant A, European urology, 2015, 10.1016/j.eururo.2015.06.054
  • Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials, Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Arjun V. Balar, Dean F. Bajorin, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt, 2023, 10.1158/1078-0432.22487295.v1
  • PCA3: a molecular urine assay for predicting prostate biopsy outcome., Groskopf J, Rittenhouse H, Fradet Y, Marks LS, Ellis WJ, Partin AW, Koo S, Day JR, Blase A, Aubin SM, Deras IL, The Journal of urology, 2008, 10.1016/j.juro.2007.11.038
  • Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration., Kassouf W, Kapoor A, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Jacobsen N, Estey E, Fairey A, Fradet Y, Chin JL, Izawa JI, Aprikian AG, Bachir BG, Urologic oncology, 2014, 10.1016/j.urolonc.2013.10.016
  • Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers., Lotan Y, Ashfaq R, Sagalowsky AI, Fajkovic H, Pummer K, Bastian PJ, Scherr DS, Isbarn H, Fradet Y, Sun M, Karakiewicz PI, Cha EK, Chromecki TF, Shariat SF, The Journal of urology, 2011, 10.1016/j.juro.2011.10.031
  • Dietary energy and nutrients in relation to preclinical prostate cancer., Moore L, Fradet Y, Bairati I, Meyer F, Nutrition and cancer, 1997, 10.1080/01635589709514612
  • Devrait-on offrir aux Canadiens le dépistage systématique du cancer de la prostate? : OUI, Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • The burden of prostate cancer in Canada., Zlotta A, Trachtenberg J, Klotz L, Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Sex steroid modulation of macrophages within the prostate tumor microenvironment., Toren P, Fradet Y, Lacombe L, Guillemette C, Gaignier F, Joncas FH, Gris T, Boibessot C, Berrehail Z, American journal of clinical and experimental urology, 2022
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Pouliot F, Fradet Y, Fradet V, Lacombe L, Nguile Makao M, Bergeron M, Beauregard JM, Morin F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder., Schmitz-Draeger BJ, Messing EM, Hodges GM, Grossman HB, Fradet Y, Baricordi O, Meier T, Huland H, Huland E, The Journal of urology, 1991, 10.1016/s0022-5347(17)38202-2
  • Can biological markers predict recurrence and progression of superficial bladder cancer?, Lacombe L, Fradet Y, Current opinion in urology, 2000, 10.1097/00042307-200009000-00013
  • Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time., Kassouf W, Lotan Y, Boorjian SA, Klatte T, Kikuchi E, Matsumoto K, Rink M, Rieken M, Masson-Lecomte A, Xylinas E, Kluth LA, Dragomir A, Shariat SF, Ploussard G, European urology, 2013, 10.1016/j.eururo.2013.09.050
  • International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy., Fradet Y, Izawa JI, Fritsche HM, Novara G, Kassouf W, Volkmer BG, Bastian PJ, Capitanio U, Karakiewicz PI, Skinner E, Tilki D, Svatek RS, Shariat SF, BJU international, 2010, 10.1111/j.1464-410x.2010.09217.x
  • pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder., Shariat SF, Sagalowsky AI, Lotan Y, Skinner E, Ficarra V, Fradet Y, Kassouf W, Gupta A, Sonpavde G, Seitz M, Novara G, Karakiewicz PI, Svatek RS, Tilki D, The Journal of urology, 2010, 10.1016/j.juro.2010.04.007
  • [Immunologic activities of lymphocytes in rats. IV. Chronologic functional variation of lymphocytes of the thoracic duct]., Daguillard F, McNicoll J, Fradet Y, L'union medicale du Canada, 1977
  • A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota., Routy B, Dridi L, Fradet Y, Isnard S, Belkaid W, Malo J, Cauchois F, Nolin-Lapalme A, Benlaifaoui M, Diop K, Ponce M, Richard C, Pidgeon R, Messaoudene M, Cancer discovery, 2022, 10.1158/2159-8290.cd-21-0808
  • A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma., Tewari HD, Venner PM, Trachtenberg J, Ramsey EW, Laroche B, Fradet Y, Elhilali M, Béland G, Cancer, 1990, 10.1002/cncr.1990.66.s5.1074
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial., KEYNOTE-361 Investigators, Loriot Y, Gunduz S, Fléchon A, Morales Barrera R, Vulsteke C, Oudard S, Fradet Y, Cheng SY, Géczi L, Matsubara N, Özgüroğlu M, Csőszi T, Powles T, The Lancet. Oncology, 2021, 10.1016/s1470-2045(21)00152-2
  • Molecular and immunologic approaches in the management of bladder cancer., Fradet Y, The Urologic clinics of North America, 1991
  • The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index., Têtu B, Fradet Y, Bernard P, Allard P, British journal of urology, 1998, 10.1046/j.1464-410x.1998.00628.x
  • Genome-wide germline correlates of the epigenetic landscape of prostate cancer., Boutros PC, Livingstone J, Heisler LE, Fraser M, Huang V, O'Connor E, Bell C, Yao CQ, Ramanand SG, Shetty A, Ahmed M, Yuan J, Gusev A, Shiah YJ, Houlahan KE, Nature medicine, 2019, 10.1038/s41591-019-0579-z
  • Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer., Fradet Y, Bussières V, LaRue H, Bergeron A, Besançon M, Ayari C, Cancer immunology, immunotherapy : CII, 2016, 10.1007/s00262-015-1789-y
  • Precision of DNA flow cytometry in inter-institutional analyses., Reeder JE, O'Connell MJ, Melamed MR, Koss LG, Fradet Y, deVere White RW, Deitch AD, Cox C, Coon JS, Wheeless LL, Cytometry, 1991, 10.1002/cyto.990120505
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival., Trudel D, Saad F, Fradet Y, Ladouceur M, Bergeron A, Hovington H, Mes-Masson AM, Latour M, Albadine R, Grosset AA, Mansoori BK, Benzerdjeb N, Sirois J, Trinh VQ, The Prostate, 2018, 10.1002/pros.23513
  • PROGRAMME SCIENTIFIQUE * SCIENTIFIC PROGRAM Association des urologues du QUébec * Qué Urological Association Congrès annuel * Annual Meeting 9 au 11 novembre 2007 * November 9-11, 2007 Hôtel Hyatt Regency Montréal Centre-Ville, Montréal PQ., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer., Guillemette C, Fradet Y, Têtu B, Turcotte V, Rouleau M, Caron P, Lacombe L, Laverdière I, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 10.1158/1078-0432.ccr-13-1100
  • ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma., Fradet Y, Harel F, Tiguert R, Têtu B, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2005, 10.1038/modpathol.3800262
  • Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder., Melamed MR, Whitmore WF, Old LJ, Oettgen HF, Pinsky CM, Herr HW, Cordon-Cardo C, Fradet Y, Huffman JL, Cancer research, 1985
  • Moderated Poster Session I: Oncology Thursday, September 29, 2016 10:15 am – 12:00 pm, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • The detection of genetic markers of bladder cancer in urine and serum., Lodde M, Fradet Y, Current opinion in urology, 2008, 10.1097/mou.0b013e32830b86d1
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Pouliot F, Rimac G, Bouchard F, Tiguert R, Dujardin T, Lacombe L, Lemay C, Fradet Y, Caron A, Fradet V, Blouin AC, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress., Lotan Y, Kamat AM, Fradet Y, Messing E, Porter M, Robinson VL, Urologic oncology, 2010, 10.1016/j.urolonc.2009.07.026
  • Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer., de Wit R, Quinn DI, Gurney H, Gerritsen W, Necchi A, Choueiri TK, Petrylak DP, Climent MA, Vogelzang NJ, Fong L, Lee JL, Fradet Y, Bellmunt J, Vaughn DJ, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10.1200/jco.2017.76.9562
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., Pouliot F, Fradet Y, Wu L, Velot L, Neveu B, Jain P, Scientific reports, 2016, 10.1038/srep33968
  • Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans., Lebel M, Grose JH, Simard J, Fradet Y, Prostaglandins and medicine, 1980, 10.1016/0161-4630(80)90087-7
  • Canadian Urological Association 62nd Annual Meeting, Quebec City, QC, June 24-27, 2006., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure., Fradet Y, Têtu B, Lacombe L, Bairati I, Moore L, Meyer F, The Journal of urology, 1999, 10.1016/s0022-5347(05)68092-5
  • Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature., Canadian surgical wait times (SWAT) initiative, Fleshner N, Tsihlias J, Siemens R, Dranitsaris G, Aprikian A, Fradet Y, The Canadian journal of urology, 2006
  • Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211., Fradet Y, Bergeron A, LaRue H, Cancer research, 1996
  • Downward trend in prostate cancer mortality in Quebec and Canada., Fradet Y, Bairati I, Moore L, Meyer F, The Journal of urology, 1999, 10.1016/s0022-5347(01)61628-8
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, Toren P, Lodde M, Fradet Y, Fradet V, Lacombe L, McMartin C, Clinical genitourinary cancer, 2019, 10.1016/j.clgc.2019.07.016
  • Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach., International Bladder Cancer Nomogram Consortium, Bochner BH, Dalbagni G, Milowsky MI, Scardino PT, Gonen M, Kattan MW, Cronin AM, Vickers AJ, Cancer, 2009, 10.1002/cncr.24615
  • Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group., De Porre P, Bruynseels J, Vangeneugden T, Rassweiler J, Brune D, Marberger JM, Denis L, Boccardo F, Tyrrell C, Johansson JE, Fradet Y, Murray R, Debruyne FJ, Urology, 1998, 10.1016/s0090-4295(98)00129-0
  • Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229
  • p53 expression in patients with advanced urothelial cancer of the urinary bladder., Lotan Y, Montorsi F, Lerner SP, Müller SC, Rigaud J, Jeldres C, Capitanio U, Nielsen ME, Bastian PJ, Ashfaq R, Fradet Y, Karakiewicz PI, Bolenz C, Shariat SF, BJU international, 2009, 10.1111/j.1464-410x.2009.08742.x
  • Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort., Rendon RA, Drachenberg D, Lattouf JB, Cagiannos I, Fairey A, Estey E, Izawa J, Chin J, Lacombe L, Fradet Y, Aprikian AG, Bell D, Kassouf W, Power NE, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11012
  • MAGE-A9 mRNA and protein expression in bladder cancer., Fradet Y, Larue H, Bergeron A, Picard V, International journal of cancer, 2007, 10.1002/ijc.22282
  • Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers., Lokeshwar VB, Getzenberg RH, Goebell P, Bono AV, Murphy WM, Schmitz-Dräger BJ, Schalken JA, Grossman HB, Hemstreet GP, Droller MJ, Marberger M, Habuchi T, Urology, 2005, 10.1016/j.urology.2005.08.065
  • Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Bachir BG, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.201
  • Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression., Guillemette C, Caron P, Yu CC, Huang CY, Rouleau M, Laverdière I, Fradet Y, Bao BY, Lacombe L, Audet-Walsh É, Huang SP, Lévesque É, Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 10.1158/1078-0432.ccr-12-2812
  • SRD5A polymorphisms and biochemical failure after radical prostatectomy., Lévesque E, Guillemette C, Girard H, Douville P, Bao BY, Huang SP, Fradet V, Fradet Y, Lacombe L, Nadeau G, Bellemare J, Audet-Walsh E, European urology, 2011, 10.1016/j.eururo.2011.06.020
  • Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL., Tremblay RR, Fradet Y, Grégoire M, Naud A, Lacombe L, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007, 10.5489/cuaj.444
  • Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival., Lachance JG, Fradet Y, Roy R, Tissue antigens, 1981, 10.1111/j.1399-0039.1981.tb01371.x
  • Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer., Lotan Y, Lerner SP, Montorsi F, Jeldres C, Capitanio U, Nielsen ME, Bastian PJ, Fradet Y, Isbarn H, Ashfaq R, Karakiewicz PI, Chade DC, Shariat SF, The Journal of urology, 2010, 10.1016/j.juro.2009.08.115
  • Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate., Trudel D, Hovington H, Mes-Masson AM, Latour M, Albadine R, Sirois J, Kougioumoutzakis A, Dionne N, Delouya G, Chagnon-Monarque S, Benzerdjeb N, Trinh VQ, Radiation oncology (London, England), 2019, 10.1186/s13014-019-1267-3
  • Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]., Shariat SF, Volkmer BG, Bastian PJ, Isbarn H, Fradet Y, Denzinger S, Skinner E, Novara G, Karakiewicz PI, Jeldres C, Svatek RS, Burger M, Fritsche HM, European urology, 2015, 10.1016/j.eururo.2015.02.007
  • 2017 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017
  • New diagnostic and prognostic tools in bladder cancer., Fradet Y, Tiguert R, Current opinion in urology, 2002, 10.1097/00042307-200205000-00011
  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)., Saad F, North S, Beer TM, Hainsworth JD, Mainwaring P, Mulders PF, Fizazi K, de Souza P, Shore ND, Logothetis CJ, de Bono JS, Smith MR, Rathkopf DE, European urology, 2014, 10.1016/j.eururo.2014.02.056
  • Total androgen blockade vs orchiectomy in stage D2 prostate cancer., Tewari HD, Venner PM, Ramsey EW, Laroche B, Fradet Y, Elhilali M, Béland G, Progress in clinical and biological research, 1987
  • Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery., Lacombe L, Fradet Y, Vigneault E, Laverdière J, Ivers H, Simard S, Savard J, Hervouet S, Journal of pain and symptom management, 2005, 10.1016/j.jpainsymman.2005.05.011
  • Quebec prostate cancer mortality dropped in 1996., Fradet Y, Bairati I, Moore L, Meyer F, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1998
  • A survey of urological manpower, technology, and resources in Canada., Morris BA, Corcos J, Fradet Y, Wilson JW, Goldenberg SL, Pommerville P, The Canadian journal of urology, 2004
  • Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest., Fradet Y, Moore L, Meyer F, Aboulkassim TO, LaRue H, Simoneau M, Oncogene, 2000, 10.1038/sj.onc.1204022
  • Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors., Fradet Y, Meyer F, Têtu B, Larue H, Moore L, Vezina MC, Lacombe L, Pfister C, Human pathology, 1999, 10.1016/s0046-8177(99)90067-9
  • Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer., Bernard P, Roberge N, Veilleux C, Allard P, Fradet Y, Tetu B, The Journal of urology, 1996, 10.1016/s0022-5347(01)66198-6
  • Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors., Fradet Y, Fair W, Melamed MR, Wartinger DD, Cordon-Cardo C, The American journal of pathology, 1992
  • Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., Pouliot F, Fradet Y, Wu L, Velot L, Neveu B, Jain P, Scientific reports, 2016, 10.1038/srep37381
  • uPM3, a new molecular urine test for the detection of prostate cancer., Chypre C, Piché L, Mâsse B, Trudel C, Elhilali M, Dessureault J, Aprikian A, Saad F, Fradet Y, Urology, 2004, 10.1016/j.urology.2004.03.052
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients., Toren P, Gilbert C, Fradet Y, Pouliot F, Leong HS, Morin F, Rouleau M, Lucien F, Joncas FH, The Prostate, 2019, 10.1002/pros.23901
  • Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy., Candas B, Fradet Y, Têtu B, Lemay M, Suburu R, Diamond P, Gomez JL, Cusan L, Labrie F, Cancer surveys, 1995
  • Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database., Estey EP, Lattouf JB, Drachenberg DE, Cagiannos I, Bell D, Rendon RA, Lacombe L, Fradet Y, Izawa JI, Chin JL, Aprikian AG, Kassouf W, Fairey AS, Urologic oncology, 2011, 10.1016/j.urolonc.2011.07.014
  • Widespread and Functional RNA Circularization in Localized Prostate Cancer., He HH, Volik S, Ahmed M, Donmez N, Zhang Y, Yousif F, Wang M, Guo H, Petricca J, Hua JT, Zeng Y, Jeon J, Soares F, Livingstone J, Xu X, Huang V, Chen S, Cell, 2019, 10.1016/j.cell.2019.01.025
  • The etiology of bladder cancer--are there any new clues or predictors of behavior?, Kagawa S, Jones P, Janknegt R, Droller M, Bollack C, Huland H, Shirai T, Fradet Y, International journal of urology : official journal of the Japanese Urological Association, 1995, 10.1111/j.1442-2042.1995.tb00481.x
  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma., KEYNOTE-045 Investigators, Gurney H, Gerritsen W, Necchi A, Choueiri TK, Petrylak DP, Climent MA, Vogelzang NJ, Fong L, Lee JL, Fradet Y, Vaughn DJ, de Wit R, Bellmunt J, The New England journal of medicine, 2017, 10.1056/nejmoa1613683
  • Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer., Bao BY, Juang SH, Lee HZ, Chang TY, Fradet Y, Lacombe L, Laverdière I, Chung IC, Chen LC, Lin VC, Huang CY, Yu CC, Guillemette C, Lévesque E, Huang SP, International journal of cancer, 2014, 10.1002/ijc.28904
  • Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction., Squire JA, Zielenska M, Marrano P, Lim G, Fradet Y, Underwood J, Vandezande K, Pond GR, Jewett MA, Gallie BL, Evans AJ, The American journal of pathology, 2004, 10.1016/s0002-9440(10)63118-5
  • Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review., Fradet V, Lacombe L, Fradet Y, Robitaille K, Lamarche B, Ben-Zvi T, Allaire J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4471
  • Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting., Black PC, Brimo F, Sridhar SS, Rendon R, North S, So A, Fairey A, Eapen L, Izawa J, Bagshaw K, Guttman DM, Kulkarni G, Breau RH, Saad F, Aprikian A, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5246
  • Prostate cancer: 4. Screening., Fradet Y, Meyer F, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1998
  • Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis., Fradet Y, Min KW, Jones PL, Bonner RB, Hurst RE, Hemstreet GP, Rao JY, Proceedings of the National Academy of Sciences of the United States of America, 1993, 10.1073/pnas.90.17.8287
  • Controversies in the management of localized prostate cancer: consensus development by Canadian urologists., Fradet Y, Klotz LH, The Canadian journal of urology, 2002
  • Lifetime occupational physical activity and incidental prostate cancer (Canada)., Fradet Y, Moore L, Meyer F, Larouche R, Bairati I, Cancer causes & control : CCC, 2000, 10.1023/a:1008936826337
  • Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen., Fradet Y, Current opinion in urology, 2009, 10.1097/mou.0b013e32832a08b5
  • Low frequency of human papillomavirus infection in initial papillary bladder tumors., Fradet Y, LaRue H, Simoneau M, Urological research, 1999, 10.1007/s002400050107
  • Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy., Burger M, Karl A, Soloway MS, Witjes JA, Kriegmair M, Mynderse LA, Fradet Y, Stenzl A, Grossman HB, The Journal of urology, 2012, 10.1016/j.juro.2012.03.007
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer., Toren P, Lacombe L, Fradet Y, Julien AS, Cyr SJ, Pelletier J, Urologic oncology, 2018, 10.1016/j.urolonc.2018.05.004
  • Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers., Droller MJ, Schalken JA, Schmitz-Dräger BJ, Goebell P, Getzenberg RH, Bono AV, Hemstreet GP, Hautmann SH, Murphy WM, Grossman HB, Habuchi T, Lokeshwar VB, Urology, 2005, 10.1016/j.urology.2005.08.064
  • Dietary fat and prostate cancer progression and survival., Moore L, Shadmani R, Bairati I, Meyer F, Fradet Y, European urology, 1999, 10.1159/000019913
  • [Molecular markers of infiltrating cancer of the bladder]., Fradet Y, Tiguert R, Rigaud J, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002
  • Dual-kidney transplants as an alternative for very marginal donors: long-term follow-up in 63 patients., Houde I, Agharazii M, Mfarrej BG, Fradet Y, Naud A, Côté I, Lachance JG, Noël R, Caumartin Y, De Serres SA, Transplantation, 2010, 10.1097/tp.0b013e3181f8f2b8
  • Influence of the diagnostic modality on the pathological stage of clinically localized prostatic cancer., Fradet Y, Bellavance GB, The Canadian journal of urology, 1994
  • Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy., Fradet Y, Lacombe L, Larue H, Laverdiere J, Latulippe E, Hovington H, Decobert M, Tiguert R, Rigaud J, The Prostate, 2004, 10.1002/pros.10329
  • The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy., Guillemette C, Lévesque É, Lacombe L, Fradet Y, Caron P, Audet-Walsh É, Flageole C, Laverdière I, Endocrine-related cancer, 2014, 10.1530/erc-14-0423
  • Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry., Têtu B, Harel F, Meyer F, Trudel D, Fradet Y, Human pathology, 2008, 10.1016/j.humpath.2007.09.021
  • Cancer-testis antigen expression in bladder cancer., LaRue H, Bergeron A, Picard V, Fradet Y, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005
  • Dietary fat and prostate cancer survival., Moore L, Fradet Y, Shadmani R, Bairati I, Meyer F, Cancer causes & control : CCC, 1999, 10.1023/a:1008913307947
  • Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?, Fradet Y, Lacombe L, Naud A, Liandier F, Grégoire M, The Journal of urology, 2002, 10.1016/s0022-5347(05)64678-2
  • Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization., Têtu B, Beaudry G, Hovington H, Beaudry G, Fradet Y, Popa I, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2007, 10.1038/modpathol.3800963
  • Total androgen blockade for metastatic cancer of the prostate., Venner PM, Trachtenberg J, Ramsey EW, Laroche B, Fradet Y, Elhilali M, Béland G, American journal of clinical oncology, 1988, 10.1097/00000421-198801102-00043
  • Prognostic markers in muscle invasive bladder cancer., Fradet Y, So A, Lessard A, Tiguert R, World journal of urology, 2002, 10.1007/s00345-002-0279-y
  • p53 predictive value for pT1-2 N0 disease at radical cystectomy., Cote RJ, Karam JA, Müller SC, Montorsi F, Jeldres C, Capitanio U, Nielsen ME, Bastian PJ, Fradet Y, Isbarn H, Ashfaq R, Karakiewicz PI, Lotan Y, Shariat SF, The Journal of urology, 2009, 10.1016/j.juro.2009.05.024
  • 2015 NS-AUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Toren P, Lacombe L, Guillemette C, Fradet Y, Dagenais F, Hovington H, D Wallis CJ, Joncas FH, Kourbanhoussen K, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21
  • Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients., Fradet Y, Lacombe L, Tiguert R, Harel F, Inman BA, The Journal of urology, 2003, 10.1097/01.ju.0000092500.68655.48
  • Neoadjuvant hormonal therapy: the Canadian experience., Candas B, Bélanger A, Fradet Y, Tetu B, Lemay M, Suburu R, Diamond P, Gomez JL, Cusan L, Labrie F, Urology, 1997, 10.1016/s0090-4295(97)00170-2
  • Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay., Chun FK, Fradet Y, Schalken JA, Abbou CC, Fisch M, Huland H, Mulders PF, Stenzl A, Marberger M, van Poppel H, Ahyai SA, de la Taille A, Auprich M, Hansen J, European urology, 2012, 10.1016/j.eururo.2012.07.030
  • Growth-regulated surface glycoproteins of human bladder cancer., Fradet Y, Gauthier J, Cancer research, 1990
  • Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas., Bernier L, Boucher L, Dufour C, Bergeron A, Parent-Vaugeois C, LaRue H, Fradet Y, International journal of cancer, 1990, 10.1002/ijc.2910460607
  • 2009 AUA-NS Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer., Grossman HB, Shen Y, Karl A, Kriegmair M, Witjes JA, Soloway MS, Mynderse LA, Fradet Y, Burger M, Stenzl A, The Journal of urology, 2010, 10.1016/j.juro.2010.06.148
  • Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer., Lacombe L, Fradet Y, Harel F, Larue H, Hovington H, Patry G, International journal of cancer, 2008, 10.1002/ijc.23240
  • PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy., Groskopf J, Rittenhouse H, Ellis WJ, Desaulniers M, Cancio AT, Aubin SM, Mathis J, Blase A, Deras IL, Fradet Y, Marks LS, Urology, 2007, 10.1016/j.urology.2006.12.014
  • A Festschrift in Honor of Edward M. Messing, MD, FACS., Trump D, Mohile S, Schwarz E, Singer E, Wu G, Rubens D, Fultz P, Ghazi A, Yeh SY, Sahasrabudhe D, Bylund K, Reeder J, Fung C, Brasacchio R, Joseph JV, Bladder cancer (Amsterdam, Netherlands), 2018, 10.3233/blc-189037
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival., Lacombe L, Fradet Y, Douville P, Meyer F, Harel F, Audet JF, Inman BA, European urology, 2005, 10.1016/j.eururo.2004.12.015
  • Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies., Old LJ, Lloyd KO, Melamed MR, Whitmore WF, Daly ME, Thomson T, Cordon-Cardo C, Fradet Y, Proceedings of the National Academy of Sciences of the United States of America, 1984, 10.1073/pnas.81.1.224
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?, Svatek RS, Kassouf W, Bastian PJ, Tagawa ST, Fradet Y, Daneshmand S, Novara G, Green DA, Kamat AM, Hansen J, Fitzgerald JP, Xylinas E, Shariat SF, Rink M, World journal of urology, 2012, 10.1007/s00345-012-0910-5
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression., Kwon ED, Lacombe L, Fradet Y, Frank I, Bergstralh EJ, Dong H, Frigola X, Sebo TJ, Inman BA, Cancer, 2007, 10.1002/cncr.22588
  • Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study., Fradet V, Lacombe L, Fradet Y, Nguilé-Makao M, Ben-Zvi T, Léger C, Allaire J, Nutrition and cancer, 2017, 10.1080/01635581.2017.1367941
  • Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome., Shariat SF, Lotan Y, Svatek RS, Skinner E, Stief CG, Sonpavde G, Ficarra V, Fradet Y, Ergün S, Novara G, Kassouf W, Karakiewicz PI, Reich O, Tilki D, European urology, 2010, 10.1016/j.eururo.2010.01.015
  • MAUB is a new mucin antigen associated with bladder cancer., Fradet Y, LaRue H, Champetier S, Bergeron A, The Journal of biological chemistry, 1996, 10.1074/jbc.271.12.6933
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., Pouliot F, Guérette D, Saad F, Klotz L, Lacombe L, Guillemette C, Fradet Y, Toren P, Dubois G, Thériault B, Déry M, Lemire F, Rouleau M, Endocrine connections, 2019, 10.1530/ec-18-0476
  • Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma., Kassouf W, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Jacobsen NE, Fairey AS, European urology, 2013, 10.1016/j.eururo.2013.06.014
  • Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015., Siemens DR, Booth C, Blais N, Brimo F, Alam T, Sridhar SS, Rendon R, North S, So A, Fairey A, Eapen L, Izawa J, Kulkarni G, Black P, Aprikian A, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016, 10.5489/cuaj.3583
  • [The use of multiparameter flow cytometry in the detection and evaluation of human bladder tumors]., Parent-Vaugeois C, Tardif M, Fradet Y, L'union medicale du Canada, 1985
  • Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study., Mayall B, Fradet Y, Cordoncardo C, Ii S, Herz F, Ooi A, International journal of oncology, 1994, 10.3892/ijo.4.1.85
  • Early detection of prostate cancer local recurrence by urinary prostate-specific antigen., Tremblay RR, Fradet Y, Lacombe L, Inman BA, Bolduc S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1074
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Lodde M, Toren P, Fradet Y, Lacombe L, Lemire F, Pycha A, Comploj E, Fradet V, Fritsche HM, Tandogdu Z, Mayr R, Ladurner C, Haider M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017
  • Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies., Miles BJ, Crawford ED, Miller GJ, Fradet Y, Hudson MA, Humphrey PA, Scardino PT, Sebo TJ, MacLennan GT, Barrett DM, Blute M, Wheeler TM, Bostwick DG, Urology, 1996, 10.1016/s0090-4295(96)00149-5
  • Cancer-testis antigen expression in bladder cancer., LaRue H, Bergeron A, Picard V, Fradet Y, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2006
  • Renal prostaglandins in postobstructive diuresis. Comparative study of unilateral and bilateral obstruction in conscious dogs., Charrois R, Talbot J, Grose JH, Lebel M, Fradet Y, Prostaglandins, leukotrienes, and essential fatty acids, 1988, 10.1016/0952-3278(88)90108-1
  • Bladder cancer markers in patient management: the current perspective., Grossman HB, Fradet Y, Schmitz-Dräger BJ, World journal of urology, 2007, 10.1007/s00345-007-0225-0
  • Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients., Shariat SF, Izawa JI, Fritsche HM, Kassouf W, Bastian PJ, Capitanio U, Isbarn H, Lotan Y, Fradet Y, Ficarra V, Skinner E, Karakiewicz PI, Svatek RS, Novara G, The Journal of urology, 2010, 10.1016/j.juro.2010.02.021
  • Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA), Vincent Fradet, Caroline Diorio, Josée Savard, Pierre Julien, Thierry Duchesne, Yves Caumartin, Thierry Dujardin, Rabi Tiguert, Michele Lodde, Paul Toren, Louis Lacombe, Yves Fradet, Roxane Tourigny, Jean-François Pelletier, Karine Robitaille, Hanane Moussa, Nutrients, 2023, 10.3390/nu15061369
  • Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy., Lotan Y, Sagalowsky AI, Rigaud J, Jeldres C, Isbarn H, Karakiewicz PI, Ashfaq R, Fradet Y, Godoy G, Bolenz C, Shariat SF, The Journal of urology, 2009, 10.1016/j.juro.2009.02.125
  • The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients., Fradet Y, Tetu B, Tiguert R, Dujardin T, Fradet V, Lacombe L, Mauermann J, European urology, 2012, 10.1016/j.eururo.2012.08.002
  • Building a Canadian Translational Bladder Cancer Research Network., Canadian Bladder Cancer Research Network, Black PC, Kassouf W, Mansure J, Fradet Y, Fradet V, Purves R, Hardy C, Eigl BJ, Toren P, Wang E, Lange D, Siemens DR, Berman DM, Koti M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6887
  • Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity., Fradet V, Bergeron A, Marette A, Julien P, Droit A, Fradet Y, Fournier É, Beaudoin L, Joly Beauparlant C, Robitaille K, Lachance G, Gevariya N, Molecular cancer research : MCR, 2020, 10.1158/1541-7786.mcr-20-0316
  • Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience., Izawa JI, Lattouf JB, Drachenberg D, Cagiannos I, Bell D, Rendon R, Lacombe L, Estey E, Fairey AS, Aprikian AG, Fradet Y, Chin JL, Kassouf W, Chalasani V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10040
  • Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group., Paton V, Ernst S, Moore R, Klotz L, Saad F, Venner P, Davis I, Fradet Y, Gleave M, Elhilali MM, BJU international, 2000, 10.1046/j.1464-410x.2000.00880.x
  • Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?, Aprikian AG, Drachenberg D, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin J, Kassouf W, Kovac E, Kotb AF, World journal of urology, 2012, 10.1007/s00345-012-0832-2
  • Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer., Fradet Y, Lacombe L, Lodde M, Urology, 2010, 10.1016/j.urology.2009.12.057
  • Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy., Shariat SF, Zerbib M, Karakiewicz PI, Lee RK, Faison T, Fradet Y, Pycha A, Kluth LA, Green DA, Brisuda A, Babjuk M, Lotan Y, Robinson BD, Rink M, Xylinas E, European journal of cancer (Oxford, England : 1990), 2013, 10.1016/j.ejca.2013.02.001
  • Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis., Fradet Y, Sargent DJ, Beaudry G, Pavey ES, Shi Q, Haince JF, Gill S, Clinical colorectal cancer, 2014, 10.1016/j.clcc.2014.12.005
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin., So AI, Gleave ME, Andersen RJ, Fradet Y, Fazli L, Adomat H, Hadaschik BA, Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, 10.1158/1078-0432.ccr-07-4475
  • Intermediate endpoint biomarkers for chemoprevention., Kelloff GJ, Moon RC, Fradet Y, Vaidya AM, Jones PL, Bonner RB, Hurst RE, Rao JY, Hemstreet GP, Journal of cellular biochemistry. Supplement, 1992, 10.1002/jcb.240501320
  • [Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer]., Bouchot O, Fradet Y, Tiguert R, Rigaud J, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002
  • Abstraits AUQ 2018, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials., Grivas P, Bajorin DF, Plimack ER, Powles T, O'Donnell PH, Sternberg CN, Necchi A, Fong L, Lee JL, Petrylak DP, Climent MA, Fradet Y, de Wit R, Bellmunt J, Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10.1158/1078-0432.ccr-21-3089
  • 2010 NS-AUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Screening for prostate cancer: a urological perspective., Fradet Y, The Canadian journal of oncology, 1994
  • Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration., Jacobsen NE, Drachenberg D, Saad F, Lattouf JB, So A, Black P, Matsumoto E, Kapoor A, Chin J, Izawa J, Bell D, Rendon R, Tanguay S, Estey E, Kassouf W, Fairey AS, BJU international, 2012, 10.1111/j.1464-410x.2012.11474.x
  • CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group., Laplante S, Chin J, Fradet Y, Chetner M, Barkin J, Jewett M, Goldenberg SL, Klotz LH, Urology, 1999, 10.1016/s0090-4295(98)00616-5
  • High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer., Fradet Y, Fradet V, Têtu B, Bergeron A, Caron A, Hovington H, LaRue H, Ayari C, Human pathology, 2013, 10.1016/j.humpath.2013.01.014
  • Canadian Urological Association guideline: Muscle-invasive bladder cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.5902
  • Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice., Fradet V, Bergeron A, Fradet Y, Julien P, Alesawi A, Diabaté L, Picard V, Robitaille K, Besançon M, Gevariya N, The Prostate, 2018, 10.1002/pros.23706
  • Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study., Navani S, Morris T, Armstrong J, Nachabe M, Tammela TL, Andersen M, Egerdie B, Fradet Y, European urology, 2007, 10.1016/j.eururo.2007.01.031
  • A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study., Canadian Urology Research Consortium, Chin JL, Zhang L, Kebabdjian M, McNeill IY, Klotz LH, European urology, 2012, 10.1016/j.eururo.2012.09.007
  • [Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma]., Gregoire M, Naud A, Fradet Y, Charrois R, Bedard G, Marois C, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1995
  • Screening for bladder cancer: the best opportunity to reduce mortality., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1192
  • Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway., Guillemette C, Lacombe L, Fradet Y, Rouleau M, Caron P, Audet-Walsh E, Laverdière I, Lévesque E, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2567
  • [Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]., Fradet Y, Lafleur L, Gauthier J, Lacombe L, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996
  • Flow and image cytometry for DNA analysis in bladder washings: improved concordance by using internal reference for flow., Faure G, Lawrence JJ, Fradet Y, Seigneurin D, Rambeaud JJ, Chabanas A, Cytometry, 1993, 10.1002/cyto.990140814
  • Alteration of the PATCHED locus in superficial bladder cancer., Fradet Y, Rousseau F, Lemieux P, LaRue H, Aboulkassim TO, Oncogene, 2003, 10.1038/sj.onc.1206513
  • A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer., PC B302/01 Study Group, Droller MJ, Nseyo U, Ritenour C, Presti J, Morales A, Fradet Y, Gomella L, Grossman HB, The Journal of urology, 2007, 10.1016/j.juro.2007.03.034
  • Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion., Audet-Walsh É, Fradet Y, Bergeron A, Bastien D, Jobin C, Neveu B, Pelletier JF, Gonthier K, Harvey M, Weidmann C, Berthiaume L, Lacouture A, Frégeau-Proulx L, Molecular metabolism, 2022, 10.1016/j.molmet.2022.101516
  • Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level., Fradet Y, Laverdière J, Lacombe L, Rigaud J, Tiguert R, The Journal of urology, 2003, 10.1097/01.ju.0000075351.51838.b3
  • Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation., Trudel D, Albadine R, Latour M, Kadoury S, Aubertin K, Azzi F, Kougioumoutzakis A, Roy N, Daoust F, Wong J, Birlea M, Nguyen T, Dallaire F, Grosset AA, PLoS medicine, 2020, 10.1371/journal.pmed.1003281
  • Regulation of in vitro lymphocyte responses. I. Adjuvant effect of lipopolysaccharide (LPS) on low-zone unresponsiveness to concanavalin A., Daguillard F, Roy R, Fradet Y, Cellular immunology, 1976, 10.1016/0008-8749(76)90157-x
  • Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA., Provost P, Pouliot F, Fradet Y, Têtu B, Bergeron A, Droit A, Joly-Beauparlant C, Majeau N, Dorval V, Ouellet-Boutin K, Diallo I, Benmoussa A, Lambert M, International journal of molecular sciences, 2021, 10.3390/ijms22189757
  • Abstracts for CUAJ Bladder Cancer Supplement Volume 3, Issue 6, Supplement 4, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer., Pouliot F, Fradet Y, Wu L, Têtu B, Jain P, Neveu B, Oncotarget, 2016, 10.18632/oncotarget.6360
  • Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro., Fradet Y, The Journal of urology, 2012, 10.1016/j.juro.2012.02.2563
  • Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy., Fradet Y, Moore L, Veilleux C, Meyer F, Maillette A, Lacombe L, International journal of cancer, 2001, 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3
  • Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer., Kassouf W, Drachenberg D, Bell D, Saad F, Lattouf JB, Lacombe L, Cagiannos I, Rendon R, Fairey A, Estey E, Izawa J, Fradet Y, Chin JL, Aprikian AG, Yafi FA, World journal of urology, 2013, 10.1007/s00345-013-1207-z
  • Toll-like receptors in normal and malignant human bladders., Fradet Y, Ménard C, LaRue H, Bergeron A, Ayari C, The Journal of urology, 2011, 10.1016/j.juro.2010.12.097
  • Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens., Leblond F, Latour M, Kadoury S, Aubertin K, Azzi F, Kougioumoutzakis A, Roy N, Daoust F, Wong J, Birlea M, Nguyen T, Grosset AA, Dallaire F, Plante A, Journal of biomedical optics, 2021, 10.1117/1.jbo.26.11.116501
  • Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy., Shariat SF, Fritsche HM, Kassouf W, Bastian PJ, Karakiewicz PI, Skinner E, Amiel GE, Lerner SP, Tilki D, Novara G, Lee R, Svatek RS, Khan MM, Sonpavde G, BJU international, 2010, 10.1111/j.1464-410x.2010.09902.x
  • Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery., Redelmeier DA, Fradet Y, Katz J, Sampson HA, Valiquette L, Jewett MA, The Journal of urology, 1999, 10.1016/s0022-5347(01)61929-3
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival., Fradet Y, Bergeron A, Lacombe L, Hovington H, Simonyan D, Brisson H, Toren P, World journal of urology, 2020, 10.1007/s00345-020-03358-x
  • Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy., Fradet Y, Lacombe L, Têtu B, Bergeron A, Harel F, Decobert M, Hovington H, LaRue H, Ayari C, European urology, 2009, 10.1016/j.eururo.2009.01.040
  • Immunological activities of rat lymphocytes. II. Isolation of suppressor cells of the mitogenic response of rat thoracic duct lymphocytes., Daguillard F, Fradet Y, Tardieu M, Cellular immunology, 1975, 10.1016/s0008-8749(75)80012-8
  • Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer., Fradet Y, Champetier S, Bergeron A, Parent-Vaugeois C, LaRue H, International journal of cancer, 1997, 10.1002/(sici)1097-0215(19970611)71:6<986::aid-ijc14>3.0.co;2-4
  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study., COU-AA-302 Investigators, Higano CS, Taplin ME, Flaig TW, Carles J, Small EJ, Shore ND, Logothetis CJ, Miller K, Sternberg CN, Mulders PF, Saad F, Fizazi K, Smith MR, Ryan CJ, The Lancet. Oncology, 2015, 10.1016/s1470-2045(14)71205-7
  • The treatment of prostate cancer: how is failure defined and how can it be minimized?, Fradet Y, The Canadian journal of urology, 1997
  • High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer., Fradet Y, Lacombe L, Hovington H, Harel F, LaRue H, Picard V, Bergeron A, International journal of cancer, 2009, 10.1002/ijc.24503
  • Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder., Skinner EC, Kamat AM, Tilki D, Dinney CP, Fritsche HM, Karakiewicz PI, Aprikian A, Bastian PJ, Fradet Y, Lerner SP, Novara G, Shariat SF, Svatek RS, Kassouf W, Urologic oncology, 2011, 10.1016/j.urolonc.2011.02.011
  • Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients., Shariat SF, Lerner SP, Ficarra V, Izawa JI, Sonpavde G, Fritsche HM, Fradet Y, Kassouf W, Karakiewicz PI, Godoy G, Seitz M, Novara G, Svatek RS, Tilki D, The Journal of urology, 2010, 10.1016/j.juro.2010.04.081
  • [International Prostate Symptom Scale. Evaluation of the usefulness of a French version]., Fradet Y, Labrecque MG, Grégoire JP, Moisan J, Canadian family physician Medecin de famille canadien, 2000
  • Northeastern Section of the American Urological Association 63(rd) Annual Meeting, New Orleans, Louisiana October 26 - 30, 2011 Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence., Fradet Y, Meyer F, Têtu B, Lacombe L, Larue H, Allard P, Moore L, Pfister C, Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
  • Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder (by Harry W. Herr, MD, Carl M. Pinsky, MD, Willet F. Whitmore, Jr, MD, Herbert F. Oettgen, MD, and Myron R. Melamed, MD). 1983., Klein FA, Fradet Y, Herr HW, Seminars in urologic oncology, 1997
  • Northeastern Section of the American Urological Association 64(th) Annual Meeting, Niagara Falls, Ontario Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy., Fradet V, Têtu B, Fradet Y, Lacombe L, Caron A, Léger C, Nguilé-Makao M, Hovington H, Desmeules P, Diagnostic pathology, 2015, 10.1186/s13000-015-0294-0
  • Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients., Shariat SF, Noldus J, Roghmann F, Boorjian SA, Kaushik D, Kassouf W, Jamzadeh A, Sharifi N, Rouprêt M, Rink M, Kent M, Xylinas E, Rieken M, Kluth LA, European urology, 2013, 10.1016/j.eururo.2013.11.040
  • Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis., Fradet Y, Haince JF, Beaudry G, Wu TT, Bot BM, Shi Q, Siemons GO, Gill S, Clancy T, Goldar-Najafi A, Meyers MO, Resnick MB, Sargent DJ, Annals of surgical oncology, 2011, 10.1245/s10434-011-1731-2
  • Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients., Shariat SF, Ficarra V, Stief CG, Izawa JI, Bastian PJ, Fritsche HM, Novara G, Fradet Y, Kassouf W, Reich O, Isbarn H, Karakiewicz PI, Svatek RS, Tilki D, The Journal of urology, 2010, 10.1016/j.juro.2009.08.145
  • Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence., Cordon-Cardo C, Fradet Y, Meyer F, Rabbani F, Moore L, Lacombe L, Osman I, LaRue H, Orlow I, The American journal of pathology, 1999, 10.1016/s0002-9440(10)65105-x
  • Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer., LATITUDE Investigators, Park YC, Kheoh T, De Porre P, Protheroe A, Feyerabend S, Ye D, Özgüroğlu M, Alekseev BY, Rodriguez-Antolin A, Matsubara N, Fein L, Tran N, Fizazi K, The New England journal of medicine, 2017, 10.1056/nejmoa1704174
  • Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype., Toren P, Bergeron A, Fradet Y, Bilodeau S, Fradet V, Pouliot F, Pelletier JF, Neveu B, Champagne A, Tav C, Lachance G, Molina O, Boibessot C, Clinical and translational medicine, 2022, 10.1002/ctm2.581
  • Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials, Petros Grivas, Blanca Homet Moreno, James Luke Godwin, Mohini Rajasagi, Junshui Ma, Andrey Loboda, Assieh Saadatpour, Jared Lunceford, Razvan Cristescu, Nicholas J. Vogelzang, Jacqueline Vuky, David I. Quinn, Howard Gurney, Winald Gerritsen, Stephane Culine, Toni K. Choueiri, Daniel Castellano, Dean F. Bajorin, Arjun V. Balar, Elizabeth R. Plimack, Thomas Powles, Peter H. O'Donnell, Cora N. Sternberg, Andrea Necchi, Lawrence Fong, Jae-Lyun Lee, Daniel P. Petrylak, Miguel A. Climent, Yves Fradet, Ronald de Wit, Joaquim Bellmunt, 2023, 10.1158/1078-0432.c.6532491.v1
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Pouliot F, Buteau FA, Beauregard JM, Fradet V, Toren P, Tiguert R, Lodde M, Lacombe L, Fradet Y, Dujardin T, Lavallée É, Dubois G, Goulet CR, Otis-Chapados S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
  • Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674
  • Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy., Shariat SF, Novara G, Kassouf W, Montorsi F, Volkmer BG, Bastian PJ, Tilki D, Lotan Y, Karakiewicz PI, Fajkovic H, Svatek RS, Cha EK, Mauermann J, Chromecki TF, World journal of urology, 2011, 10.1007/s00345-011-0772-2
  • Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31., Fradet Y, Rousseau F, LaRue H, Aboulkassim TO, Simoneau M, Oncogene, 1999, 10.1038/sj.onc.1202277
  • Human papillomavirus in transitional cell carcinoma of the urinary bladder, Fradet Y, Simoneau M, LaRue H, Clinical cancer research : an official journal of the American Association for Cancer Research, 1995
  • Quality indicators in the management of bladder cancer: A modified Delphi study., Kassouf W, Izawa J, Gotto G, Fradet Y, Fleshner N, Fairey A, Eapen L, Drachenberg D, Chung P, Chin J, Brimo F, Booth C, Blais N, Black P, Aprikian A, Khare SR, Urologic oncology, 2017, 10.1016/j.urolonc.2016.12.003
  • Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma., Black PC, Fairey AS, Fradet Y, Lacombe L, Saad F, Lattouf JB, Shayegen B, Kapoor A, Chin J, Izawa J, Bell D, Rendon RA, Kassouf W, Hamidizadeh R, Locke JA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5377
  • Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment., Gonen M, Sagalowsky AI, Lotan Y, Fradet Y, Daneshmand S, David SG, Novara G, Fajkovic H, Chromecki TF, Svatek RS, Cha EK, Rink M, Ehdaie B, Shariat SF, European urology, 2011, 10.1016/j.eururo.2011.10.011
  • Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up., Bajorin DF, Quinn DI, Gurney H, Gerritsen W, Necchi A, Choueiri TK, Petrylak DP, Climent MA, Vogelzang NJ, Fong L, Lee JL, Vaughn DJ, Bellmunt J, Fradet Y, Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 10.1093/annonc/mdz127
  • Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies., Noël R, Lachance JG, Roy R, Fradet Y, Clinical nephrology, 1982
  • Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network., Waldman FM, Taube SE, Peng A, Grossman HB, Fradet Y, Faraggi D, Cote R, Cordon-Cardo C, Aamodt R, McShane LM, Clinical cancer research : an official journal of the American Association for Cancer Research, 2000
  • Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES., Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Safety and outcome of early catheter removal after radical retropubic prostatectomy., Fradet Y, Rigaud J, Tiguert R, Urology, 2004, 10.1016/j.urology.2003.10.042
  • Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder., LaRue H, Lafleur L, Fradet Y, Journal of cellular biochemistry. Supplement, 1992, 10.1002/jcb.240501319
  • Cell surface differentiation antigens of normal urothelium and bladder tumors., Cordon-Cardo C, Fair WR, Fradet Y, Sheinfeld J, Reuter VE, Dalbagni G, Seminars in surgical oncology, 1992, 10.1002/ssu.2980080508
  • Invasive bladder cancer: time is of the essence., Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008, 10.5489/cuaj.483
  • A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer., Guillemette C, Chevalier S, Carmel M, Saad F, Aprikian A, Fradet Y, Simonyan D, Turcotte V, Lacombe L, Caron P, Lévesque E, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-18-1002
  • 2014 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia., Klotz LH, Schick E, Orovan WL, Trachtenberg J, Fradet Y, Beland G, Boake RC, Casey RW, Barkin J, Ramsey EW, Elhilali MM, Urology, 1996, 10.1016/s0090-4295(99)80449-x
  • Genomic hallmarks of localized, non-indolent prostate cancer., Boutros PC, Prokopec SD, Xie M, Fox NS, Masella AP, Lin X, Yousif F, Shiah YJ, Huang V, Livingstone J, Heisler LE, Yamaguchi TN, Sabelnykova VY, Fraser M, Nature, 2017, 10.1038/nature20788
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial., DANUBE study investigators, Eigl BJ, Bamias A, Bögemann M, De Giorgi U, Lee JL, Park SH, Ogawa O, Petrylak DP, Loriot Y, Galsky MD, Castellano D, van der Heijden MS, Powles T, The Lancet. Oncology, 2020, 10.1016/s1470-2045(20)30541-6
  • Reply from authors re: Martin Spahn, Steven Joniau. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol 2013;64:26-8: adjuvant versus salvage radiotherapy in patients with positive surgical margins at radical prostatectomy: that is the question., Fradet Y, Fradet V, Mauermann J, European urology, 2012, 10.1016/j.eururo.2012.10.047
  • Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective., Pouliot F, Dujardin T, Deschênes-Rompré MP, Cloutier J, Caumartin Y, Bureau M, Bolduc-Mokhtar A, Bolduc S, Blouin AC, Blais AS, Bélanger L, Turcotte B, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7819
  • Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study., Pinthus J, Gopaul D, Lukka H, Luke P, Mousavi N, Lavallee L, Chin J, Brown I, Klotz L, Niazi T, Siemens R, Duceppe E, Shayegan B, Fradet V, Leong DP, The Journal of urology, 2020, 10.1097/ju.0000000000000714
  • Contemporary Management of Bladder Cancer: Identifying patients who are at risk., Fradet Y, Bell D, Canadian family physician Medecin de famille canadien, 1991
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study., Elhilali MM, Afridi SK, Perreault JP, Pommerville PJ, Boake RC, Fradet Y, Nickel JC, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1996
  • Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer., Foley R, Fink C, Dekaban GA, Mukherjee SD, Hotte S, Landry C, Peretz Y, Favre D, Yassine-Diab B, Eady R, Salter RD, Finn OJ, Bergeron A, Major P, Scheid E, Cancer immunology research, 2016, 10.1158/2326-6066.cir-15-0189
  • Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma., Izawa JI, Saad F, Fradet Y, Bell D, Lattouf JB, So A, Tanguay S, Lacombe L, Black P, Kapoor A, Fairey A, Jacobsen N, Rendon R, Chin J, Kassouf W, Williams AK, Urologic oncology, 2013, 10.1016/j.urolonc.2011.12.004
  • Phenotypic characterization of bladder cancer., Fradet Y, European urology, 1998, 10.1159/000052250
  • Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial., GALAHAD investigators, Zhao X, Espina BM, Mason GE, Danila DC, Olmos D, Ståhl O, Saad F, Chi KN, George DJ, Yu EY, Lara PN, Efstathiou E, Sandhu S, Scher HI, Smith MR, The Lancet. Oncology, 2022, 10.1016/s1470-2045(21)00757-9
  • Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line., Stirpe F, Fradet Y, Lafleur L, Bolognesi A, Polito L, Battelli MG, International journal of cancer, 1996, 10.1002/(sici)1097-0215(19960208)65:4<485::aid-ijc16>3.0.co;2-9
  • Characterization of lymphocytotoxic antibodies in renal transplantation., Hebert J, Fradet Y, Lachance JG, Roy R, Transplantation, 1981, 10.1097/00007890-198101000-00008
  • Sharing the responsibility of prostate cancer risk reduction, Tanguay S, Goldenberg L, Fradet Y, Klotz L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study., PC B302/01 Study Group, Droller MJ, Albala D, Cookson M, Lerner S, Gomella L, Grossman HB, Fradet Y, The Journal of urology, 2007, 10.1016/j.juro.2007.03.028
  • Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes., Fradet Y, Meyer F, Tetu B, Veilleux C, Lacombe L, Moore L, Larue H, Pfister C, International journal of cancer, 2000, 10.1002/(sici)1097-0215(20000120)89:1<100::aid-ijc16>3.0.co;2-q
  • Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience., Kassouf W, Drachenberg D, Saad F, Bell D, Lattouf JB, Lacombe L, Cagiannos I, Fairey A, Estey E, Rendon R, Izawa J, Chin JL, Fradet Y, Aprikian AG, Yafi FA, BJU international, 2012, 10.1111/j.1464-410x.2012.11133.x
  • A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment., Theodorescu D, Lee JK, Hartmann A, Stöckle M, Lehmann J, Fradet Y, Moskaluk CA, Ding KF, Ru Y, Dancik G, Baras AS, Smith SC, The Lancet. Oncology, 2011, 10.1016/s1470-2045(10)70296-5
  • Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression., Droit A, Fradet Y, Collins C, Boutros PC, Livingstone J, Martin-Magniette ML, Picard V, Hovington H, Légaré XP, Leclercq M, Molina OE, Vittrant B, Bergeron A, Oncoimmunology, 2020, 10.1080/2162402x.2020.1851950
  • Markers of prognosis in superficial bladder cancer., Fradet Y, Seminars in urology, 1992
  • Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial., Têtu B, Lemay M, Fradet Y, Suburu R, Koutsilieris M, Diamond P, Gomez J, Cusan L, Dupont A, Labrie F, Clinical and investigative medicine. Medecine clinique et experimentale, 1993
  • Should Canadians be offered systematic prostate cancer screening? Yes., Fradet Y, Canadian family physician Medecin de famille canadien, 2007
  • Blood management and radical retropubic prostatectomy: Quebec experience., Fradet Y, Lacombe L, The Canadian journal of urology, 1999
  • Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer., Fradet Y, Lacombe L, Rousseau F, Pfister C, Harel F, Bergeron A, Larue H, Decobert M, The Journal of urology, 2006, 10.1016/s0022-5347(05)00653-1
  • DNA slit-scan flow cytometry of bladder irrigation specimens and the importance of recognizing urothelial cells., Frank IN, Cockett AT, Fradet Y, Cosgriff JM, Robinson RD, O'Connell MJ, Reeder JE, Wheeless LL, Cytometry, 1991, 10.1002/cyto.990120207
  • Predictors of cancer-specific mortality after disease recurrence following radical cystectomy., Bladder Cancer Research Consortium, Bastian PJ, Lotan Y, Chun FK, Novara G, Cha EK, Aziz A, Green DA, Hansen J, Brisuda A, Babjuk M, Fritsche HM, Xylinas E, Kent M, Lee DJ, Rink M, BJU international, 2012, 10.1111/j.1464-410x.2012.11433.x
  • Immunoanatomic dissection of the human urinary tract by monoclonal antibodies., Old LJ, Melamed MR, Oettgen HF, Lloyd KO, Whitmore WF, Finstad CL, Fradet Y, Bander NH, Cordon-Cardo C, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 1984, 10.1177/32.10.6384360
  • 2009 CUA Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy., Shariat SF, Fritsche HM, Kassouf W, Bastian PJ, Karakiewicz PI, Skinner E, Amiel GE, Lerner SP, Tilki D, Novara G, Lee R, Svatek RS, Khan MM, Sonpavde G, The Journal of urology, 2011, 10.1016/j.juro.2010.11.082
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., Fradet Y, Dujardin T, Tiguert R, Pouliot F, Lacombe L, Ben-Zvi T, Bergeron A, Caron A, Léger C, Lévesque J, Lodde M, Nguile-Makao M, Toren P, Fradet V, BJU international, 2017, 10.1111/bju.14041
  • Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy., Canadian Uro-Oncology Group, Chatterjee S, Chin J, Barkin J, Nam R, Fradet Y, Jewett MA, Goldenberg SL, Klotz LH, The Journal of urology, 2003, 10.1097/01.ju.0000081404.98273.fd
  • Northeastern Section of the AUA 72nd Annual Meeting Abstracts, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis., Lebel M, Fradet Y, Lacombe L, Têtu B, Larue H, Lacombe C, Brisson H, Hovington H, Paquet ÉR, Biomarkers in medicine, 2015, 10.2217/bmm.14.115
  • The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience., Rendon RA, Matsumoto E, Saad F, Lattouf JB, So A, Chin J, Tanguay S, Black P, Izawa J, Fairey A, Jacobsen N, Kapoor A, Lacombe L, Bell DG, Kassouf W, Mason RJ, Urology, 2012, 10.1016/j.urology.2011.11.058
  • The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy., Lévesque É, Guillemette C, Douville P, Fradet V, Fradet Y, Lacombe L, Bellemare J, Audet-Walsh É, European urology, 2011, 10.1016/j.eururo.2011.12.021
  • Bicalutamide (Casodex) in the treatment of prostate cancer., Fradet Y, Expert review of anticancer therapy, 2004, 10.1586/14737140.4.1.37
  • Abiraterone in metastatic prostate cancer without previous chemotherapy., COU-AA-302 Investigators, Basch E, Mulders PF, Carles J, Ng S, Piulats JM, Mainwaring P, Fizazi K, de Souza P, Logothetis CJ, Molina A, de Bono JS, Smith MR, Ryan CJ, The New England journal of medicine, 2012, 10.1056/nejmoa1209096
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Pouliot F, Beauregard JM, Fradet Y, Makao-Nguile M, Fradet V, Lacombe L, Tiguert R, Dujardin T, Duchesnay N, Blouin AC, Buteau FA, Bergeron M, Lavallée E, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • Significance of MMP-2 expression in prostate cancer: an immunohistochemical study., Têtu B, Harel F, Meyer F, Fradet Y, Trudel D, Cancer research, 2003
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality., Lacombe L, Fradet Y, Tran VT, Inman BA, Cancer, 2009, 10.1002/cncr.24339
  • Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?, Lacombe L, Fradet Y, Meyer F, Harel F, LaRue H, Decobert M, Cancer, 2008, 10.1002/cncr.23627
  • Abstraits AUQ 2016 Programme Scientifique - Session 1, , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts : National Harbor, MD, USA. 9-13 November 2016, , Journal for immunotherapy of cancer, 2016
  • Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study., Lotan Y, Sagalowsky AI, Müller SC, Nielsen ME, Bastian PJ, Jeldres C, Montorsi F, Isbarn H, Fradet Y, Ashfaq R, Karam JA, Godoy G, Karakiewicz PI, Shariat SF, Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, 10.1158/1078-0432.ccr-08-2554
  • Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort., Shariat SF, Volkmer BG, Bastian PJ, Isbarn H, Fradet Y, Denzinger S, Skinner E, Novara G, Karakiewicz PI, Jeldres C, Svatek RS, Burger M, Fritsche HM, European urology, 2009, 10.1016/j.eururo.2009.09.024
  • Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302., Ryan CJ, Hainsworth JD, Mainwaring P, Mulders PF, Fizazi K, de Souza P, Logothetis CJ, de Bono JS, Smith MR, Rathkopf DE, Van Poppel H, Shore N, Saad F, European urology, 2015, 10.1016/j.eururo.2015.04.032
  • Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group., Robert J, Bourget L, Tardif M, Fradet Y, Cancer research, 1990

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Florin Constantin - Maîtrise avec mémoire - 2010/05
  • Laurence Bérubé Cooey - Maîtrise avec mémoire - 2012/01
  • Ehsan Dadvar - Maîtrise avec mémoire - 2014/01
  • Denise St-Onge - Maîtrise avec mémoire - 2016/05
  • Marjorie Besancon - Doctorat - 2017/09
  • Oscar Eduardo Molina - Maîtrise avec mémoire - 2018/05
  • Benjamin Vittrant - Doctorat - 2021/01
  • Fahimeh Aeineh Negin - Maîtrise avec mémoire - 2022/09
  • Sébastien Le Batteux - Doctorat - 2022/09
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.